Gene Level Profiles in ALS Are Informative, but Lack Diagnostic Value, Study Finds

Determining genetic profiles from patients’ blood samples can provide a broad view of the biological processes involved in amyotrophic lateral sclerosis (ALS). However, this information may not add valuable diagnostic information because it can’t accurately discriminate ALS cases from conditions that mimic the disease, according to researchers. Their study,…

Having ALS is certainly no laughing matter, but I’ve found that living with it can give rise to many humorous moments. Most of my “laugh out loud” episodes are the result of misunderstood conversations, encounters with Murphy’s Law, or while attempting to open “tamper-proof” pill bottles. I’ll…

The noninvasive detection of changes in the blood specific to amyotrophic lateral sclerosis (ALS) may improve the diagnosis of the disease, according to researchers. Their study, “Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis,” appeared in the journal…

A recent study highlights a previously unknown function of the TDP-43 protein in nerve cells that may contribute to the progression of amyotrophic lateral sclerosis (ALS). The finding adds a new layer of knowledge that could help to better understand the mechanisms involved in ALS development and progression. TDP-43 protein…

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded Aquinnah Pharmaceuticals $3.4 million to continue to develop and advance potential therapies to treat amyotrophic lateral sclerosis (ALS). This NINDS grant is the second given to Aquinnah to help support its novel approach for the treatment of…

ALS has been a blessing to me. You read that right — a blessing. Oh, it has been many other things: ordeal, handicap, curse, millstone, scene-stealer, tormentor, humiliator, predator, interloper, income garnisher, bully, danger, satirist, infidel, and terrorist. It strives, ultimately, to be my terminator. But, if not for ALS,…

The National Institute of Neurological Disorders and Stroke (NINDS) awarded $3.7 million to AcuraStem to support the development of a small molecule drug to treat C9orf72 gene-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The Small Business Innovation Research (SBIR) fast-track grant (R44NS105156) will promote the development…

Patients with amyotrophic lateral sclerosis (ALS) show alterations in the activity of their masticatory (jaw) muscles, impairing their ability to chew, according to the results of a small study. The study, “Alterations in the stomatognathic system due to amyotrophic lateral sclerosis,” was published in the Journal of Applied…